Padeliporfin di-potassium - Steba Biotech

Drug Profile

Padeliporfin di-potassium - Steba Biotech

Alternative Names: Padeliporfin - Steba Biotech; Palladium bacteriopheophorbide monolysine taurine; Stakel; TOOKAD Soluble; WST 11

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Steba Biotech
  • Developer Memorial Sloan-Kettering Cancer Center; Steba Biotech; Weizmann Institute of Science
  • Class Antineoplastics; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Prostate cancer
  • Phase I/II Renal cancer
  • Phase I Oesophageal cancer
  • Suspended Choroidal neovascularisation
  • No development reported Cholangiocarcinoma; Non-small cell lung cancer

Most Recent Events

  • 02 Oct 2017 Phase-II clinical trials in Prostate cancer in USA (IV) (NCT03315754)
  • 15 Sep 2017 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of padeliporfin for Prostate cancer
  • 26 Apr 2017 Phase-I clinical trials in Oesophageal cancer (In adults, In the elderly, Metastatic disease) in Israel, USA (IV) (NCT03133650)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top